Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Novasep Discovers Explosive Properties of Togni Reagent II

Published: Wednesday, April 17, 2013
Last Updated: Wednesday, April 17, 2013
Bookmark and Share
Novasep reclassifies reagent and informs market about new safety measures required.

Novasep has announced that its R&D team has discovered and characterized the explosive properties of the Togni reagent II and intermediates at the Novasep Leverkusen site in Germany.

The findings have been published in the March edition of the journal Organic Process Research and Development.

Togni reagent II (1-(trifluoromethyl)-1,2-benziodoxol-3(1H)-one, 1) is a versatile reagent for the electrophilic introduction of trifluoromethyl groups. It is used in pharmaceutical manufacturing. It is also widely used in universities.

Novasep conducted a Koenen test on a sample of Togni Reagent II prepared in their kilolab, in which the reagent was shown to be highly explosive.

Another critical property of the Togni Reagent II clarified by the Novasep team is its fast combustion when ignited. The combustion factor was measured as BZ6, the same classification as black powder.

This discovery has resulted in a revised classification for handling and transportation of the Togni reagent II, which must now be approved by national competent authorities.

Novasep has also informed companies known to market the compound, who will relay the safety measures required to handle the reagent.

Tests were conducted in the Novasep Leverkusen plant. The plant has German government authorization to handle energetic materials and operate hazardous reactions from lab to thousands tons scale.

This has enabled Novasep to develop reliable and cost-efficient processes that satisfy regulatory requirements whilst maintaining safety for technical staff and its plants.

The skill developed by Novasep includes managing large-scale reactions that use sodium azide, reactive metals, diazomethane and diborane (both in gaseous form), hydrazine, ozone and nitroalkanes.

These chemical reactions are often more direct and cost-efficient than traditional routes of synthesis. They generally create fewer by-products and have a high yield and productivity.

“Novasep has used our 140 years experience and the knowledge of our R&D team in highly energetic reagents and reactions as well as our specialized equipment to be able to identify another set of dangerous properties of a commonly used compound,” said Dr. Jan Haller, senior scientist, process development, Novasep.

Dr. Haller continued, “We consider it very important to share this knowledge with scientific, manufacturing and regulatory communities to ensure that this compound is treated in a safe manner.”

“The work completed by Novasep regarding the Togni Reagent II will contribute to a more deliberate and responsible handling of the reagent used by so many research groups," said Professor Togni, professor of organometallic chemistry at the Laboratory of Inorganic Chemistry, ETH Zurich and inventor of the reagent.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More Than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Novasep and GTP Technology Announces Partnership
Company has announced partnership with GTP Technology for the development of therapeutic and diagnostic candidates for European biopharmaceutical clients.
Friday, March 25, 2016
Novasep, GTP Technology Join Forces
Partnership offers biotech firms full CDMO services at all development stages from gene to end product.
Tuesday, March 22, 2016
Synthesis and Kilo Lab Extensions to US facility
Company builds a new synthesis laboratory and a kilo lab for US facility.
Tuesday, February 09, 2016
Novasep Adds Synthesis and Kilo Lab Extensions to US Facility
Enhanced capabilities bring Novasep’s unique range of specialized drug development technologies within easier reach of North American customers.
Saturday, February 06, 2016
Novasep, Advanced Biotherapeutics Team Up
Strategic partnership creates a world leading CDMO offer to supply AAV-based viral vectors, an increasingly attractive therapeutic platform for gene therapy.
Wednesday, January 13, 2016
Novasep Strengthens its Advisory Board
Professors Alois Fürstner and Alois Jungbauer, renowned experts in catalysis and purification processes, will help boost innovation at Novasep
Tuesday, September 29, 2015
Novasep Invests €10M to Reinforce its Bioconjugation Services
Expansion marks the company’s readiness for full range Antibody Drug Conjugates CMO services.
Thursday, June 25, 2015
Novasep Further Strengthens Management Team
Pierre-Louis Mikus joins as chief legal officer and Bertrand Waymel is promoted to group human resources director.
Wednesday, May 06, 2015
Novasep and Celladon Execute MYDICAR API Supply Agreement
An innovative, genetically-targeted enzyme replacement therapy based on AAV1/SERCA2a.
Thursday, March 26, 2015
Novasep & Celladon Partner
Novasep has entered into an agreement with Celladon, to commercially biomanufacture Celladon’s Mydicar API.
Tuesday, February 24, 2015
Novasep Enters into an Agreement with Celladon
Company selected to commercially biomanufacture Celladon's Mydicar API.
Thursday, February 19, 2015
Novasep Opens New Office in Thailand
Novasep’s extended presence in South East Asia strengthens the company’s ability to address growing needs in the region’s food and feed markets.
Saturday, December 27, 2014
Novasep to Sell its Bahamian Plant to Local Investor
Company has completed the sale of the Bahamian facility and related business of its fully-owned subsidiary, Pharmachem.
Thursday, October 09, 2014
Novasep Passes FDA Inspections on Two Sites
Novasep wins approval to produce new molecular entity for US market.
Thursday, July 24, 2014
Novasep’s €4 M ADC Manufacturing Plant Extension Commissioned
The new Highly Potent API manufacturing capacity at the Le Mans facility will boost Novasep’s ability to meet customer demand for producing anti-cancer therapies.
Friday, May 16, 2014
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Connectome Map More Than Doubles Human Cortex’s Known Regions
Researchers at NIH have developed software that automatically detects the “fingerprint” of each of these areas in an individual’s brain scans.
Discovered Through ‘Big Data’ Analysis
Researchers at the SBP have identified over 100 new genetic regions that affect the immune response to cancer.
Human Stem Cells to Rapidly Generate Bone, Heart Muscle
A new study shows that combining positive and negative signals can quickly and efficiently steer stem cells down complex developmental pathways to become specialized tissues that could be used in the clinic.
New Mechanism of Tuberculosis Infection
Researchers at UTSW Medical Center have identified a new way that tuberculosis bacteria get into the body, revealing a potential therapeutic angle to explore.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer and that, when deleted in the lungs of mice, prevents the cancer from forming.
Eliminating Doubt in Criminal Investigations
New ASU certificate to help curb error, misunderstanding in the quest for justice.
Determination of 13 Organic Toxicants in Human Blood
Researchers have utilised liquid-liquid extraction coupling HPLC-MS/MS to identify and quantify organic toxicants in human blood.
A Novel Cell Culture Model For Forensic Biology Experiments
Researchers have developed a new cell culture model which provides an efficient research tool in forensic biology.
Rhino DNA Bank Aids Anti-Poaching Fight
At the University of Pretoria's Veterinary Genetics Laboratory (VGL) at Onderstepoort, Dr Cindy Harper and her team have developed a ground-breaking technique to collect and catalogue DNA from rhinos and rhino horns.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!